

Table 1.1 Therapeutic monoclonal antibodies, Fc fusion and Fab conjugates approved or in review in the European Union or United States^a

Brand name	Molecule	Type of mAb	Year approved	Company	Indication	Administration route
Abthrax	Raxibacumab	Anti-B; anthrax PA; human IgG1	(2012)	Human Genome Sciences/Glaxo Smith Kline	Anthrax	SC
Actemra	Tocilizumab	Anti-IL6R; humanized IgG1	2009 (2010)	Genentech/Roche	Rheumatoid arthritis	IV infusion
Adcetris	Brentuximab vedotin	Anti-CD30; chimeric IgG1 immunoconjugate	2012 (2011)	Seattle Genetics	Hodgkin's lymphoma	IV infusion
Amevive	Alefacept	Fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to a human IgG1 Fc	(2003) withdrawn from the market in 2011	Astellas Pharma US, Inc.	Moderate to severe psoriasis with plaque formation, where it interferes with lymphocyte activation	IV or IM
Arcalyst	Rilonacept	Fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component (IL-1R1) and IL-1 receptor accessory protein (IL-1RAcP) linked in-line to an Fc human IgG1 that binds and neutralizes IL-1	(2008)	Regeneron	Cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal onset multi-system inflammatory disease (not approved in the US on this indication)	SC
Arzerra	Ofatumumab	Anti-CD20; human IgG1	2010 (2009)	Glaxo Smith Kline	Chronic lymphocyte leukemia	IV infusion